Reasons for guideline non-adherence in older and younger women with advanced stage ovarian cancer.

Autor: van Walree IC; Department of Internal Medicine, Diakonessenhuis Utrecht, the Netherlands. Electronic address: ivwalree@diakhuis.nl., Bretveld R; Netherlands Comprehensive Cancer Organisation, the Netherlands., van Huis-Tanja LH; Department of Internal Medicine, Diakonessenhuis Utrecht, the Netherlands., Louwers JA; Department of Gynecology, Diakonessenhuis Utrecht, the Netherlands., Emmelot-Vonk MH; Department of Geriatric Medicine, University Medical Center, Utrecht, the Netherlands., Hamaker ME; Department of Geriatric Medicine, Diakonessenhuis Utrecht, the Netherlands.
Jazyk: angličtina
Zdroj: Gynecologic oncology [Gynecol Oncol] 2020 Jun; Vol. 157 (3), pp. 593-598. Date of Electronic Publication: 2020 Mar 11.
DOI: 10.1016/j.ygyno.2020.03.005
Abstrakt: Objective: This study aims to assess the reasons for guideline non-adherence in women with advanced stage ovarian cancer and whether these reasons differ according to age.
Methods: All women diagnosed with advanced stage ovarian cancer, International Federation of Gynecology and Obstetrics (FIGO) IIb-IV, between 2015 and 2018 were selected from the Netherlands Cancer Registry. Treatment patterns and reasons for guideline non-adherence were analyzed according to age groups.
Results: 4210 women were included, of whom 34%, 33%, 26%, and 8% were aged <65, 65-75, 75-85, and ≥85 years respectively. With advancing age, less women received guideline-adherent treatment (decreasing from 70% to 2% in women aged <65 and ≥85 years respectively) and more women received best supportive care only (ranging from 4% to 69% in women aged <65 and ≥85 years respectively). The most prevalent reasons for guideline non-adherence differed according to age and included patient preference in older women, and functional status and extent of disease in younger women.
Conclusions: Most older women did not receive guideline-adherent care and patient preference was the most common reason for this decision. This knowledge provides insight in the current treatment decision-making process and highlights the importance of eliciting patient treatment preferences. Further prospective research is necessary to study the underlying motivation for women to decline guideline care and the extent to which shared decision-making influences treatment choice.
Competing Interests: Declaration of competing interest JA Louwers is consultant for DySISmedical. All other authors have declared no conflicts of interest.
(Copyright © 2020 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: